Exclusion Criteria:~1. Presence of clinically significant disorders of the central nervous system other than
Alzheimer's disease, such as Lewy Body Disease, Parkinson's disease, hydrocephalus, epilepsy, demyelinating
disease, brain tumors, or psychiatric disorders (such as schizophrenia, or severe affective disorders).~2.
Serious or unstable hematologic, hepatic, renal, pulmonary, cardiac, or other medical disease.~3. Abnormal
liver function tests (ALT or AST) or creatine kinase (CK) upon repeat testing.~4. Chronic hepatitis B or C
infection, indicated by positive HBSAg, or HCV-Ab with HCV RNA presence.~5. Known history of human
immunodeficiency virus (HIV) infection.~6. Known immune disorder that has a history of requiring treatment with
immunosuppressive drugs within the past 1 year.~7. Have a drug or alcohol abuse within 12 months prior to
screening.~8. Clinically significant laboratory abnormalities at screening.~9. Screening ECG showing repeated
QTcF > 480 msec, or other clinically significant ECG abnormalities.~10. Clinically significant structural brain
abnormalities, such as hydrocephalus or intra-axial brain tumors.~11. Participation in another investigational
study within 30 days or 5 half-lives prior to screening, whichever is greater.~12. Participation in another
study that would have cognitive testing during the duration of this study.~13. History of Covid19 or other
viral infections within 3 months.~14. Have a clinically significant medical, surgical, laboratory, or
behavioral abnormality, which in the judgment of the Investigator makes the subject unsuitable for the study.
